Resmed share price dips despite profit and dividend boost

Profits and dividends are up, so why is the Resmed share price down?

| More on:
a young woman props her hand under the face as she pokes her head out from under a luxurious doona in a bedroom decorated with flowers and a stylish lamp.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Resmed share price is down 3.5% in afternoon trading
  • The US-based company booked a 12% increase in revenue and a 9% increase in profit year over year 
  • Holders of Resmed shares on the ASX will receive 4.4 US cents per share as dividends on September 22

The Resmed CDI (ASX: RMD) share price is down around 3.5% at $33.42 in afternoon trading. This comes after the US-based sleep apnoea medical device company released its full-year results to the ASX this morning.

As my colleague James wrote, ResMed Inc (NYSE: RMD) booked a 12% increase in revenue year over year to US$3.6 billion. It finished the year with an underlying net profit of US$850.8 million, up 9% on FY21.

Revenue and profits up

As James points out, ResMed's underlying net profit was slightly above market consensus expectations of US$825.6 million.

A recall by competitor Royal Philips in June 2021 provided a revenue boost for ResMed in FY22.

Management estimates that US$60 million to US$70 million in incremental fourth-quarter revenue was related to the recall. That implies an annual total of US$220 million to US$260 million.

Inflation started to bite in FY22, with higher freight and manufacturing costs impacting margins.

Over FY22, the Resmed share price slipped by about 7%.

Resmed dividends up

ResMed declared a final quarterly cash dividend of 44 US cents, up 5% on the prior corresponding period. But that's what ResMed Inc shareholders (owners of the NYSE-listed shares) will get. It's different for ASX shareholders, who own Resmed CDI shares.

Remember ResMed is a US-domiciled company listed on the New York Stock Exchange. The Resmed shares listed on the ASX are CHESS depositary interests (CDIs) which "confer a beneficial interest in the underlying financial product to which it relates", explains the ASX.

This beneficial interest is on a ratio of 10:1 for owners of the ASX shares. So, Resmed CDI shareholders will receive 4.4 US cents per share as dividends. This currently converts to 6.2 cents in Australian currency. The payment date is 22 September.

So, why is the Resmed share price down?

The company exceeded consensus profit expectations, and it's going to pay a higher dividend this year. So why is the Resmed share price down?

Well, the dip might not have anything to do with investors' reactions to the results. The market as a whole is down today.

The S&P/ASX 200 Index (ASX: XJO) is off 0.73% and the S&P/ASX 200 Health Care Index (ASX: XHJ) is down 1.81%.

In fact, healthcare is the second worst performing sector today behind the S&P/ASX 200 A-REIT Index (ASX: XPJ), which is down 1.87%. The only sectors in the green are energy and communications.

So, it might simply be a case of the Resmed share price being dragged down, along with many other ASX healthcare shares, by the broader sector and market today.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 6 March 2025

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Top broker says Mesoblast shares can rocket 100%

Big returns could be on offer from this biotech according to Bell Potter.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Healthcare Shares

Forget Trump! Here are 3 reasons to buy this $32 billion ASX 200 healthcare share today

A leading expert forecasts more growth ahead for this $32 billion ASX 200 healthcare company.

Read more »

A scientist examining test results.
Healthcare Shares

1 ASX dividend stock down 43% I'd buy right now

This business could provide both dividends and growing, defensive earnings.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Why FDA approval could turn this ASX All Ords company into a multibagger

Despite surging more than 230% in the past year, this company might be on its way to becoming a much…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Broker laments 'catastrophic negative surprise' that highlights the risks with these types of ASX shares

Canaccord Genuity recommends a 'basket approach' when investing in these types of stocks.

Read more »

A worried woman looks at her phone and laptop, seeking ways to tighten her belt against inflation.
Healthcare Shares

This ASX share potentially 'has no value from here', says broker

This is every investor's worst nightmare.

Read more »

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Healthcare Shares

Should I buy Fisher & Paykel or ResMed shares?

Let's see which of these two names could be best buys.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

This company has entered a trading halt, is it about to announce FDA approval?

This regenerative medicine company is up more than 260% in the last year.

Read more »